Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial.

摘要: OBJECTIVE —Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional formulations. Accordingly, has been compared with NPH respect glycemic control (HbA 1c , prebreakfast glucose levels and variability, hypoglycemia) timing administration. RESEARCH DESIGN AND METHODS —People type 1 diabetes ( n = 408) were randomized in an open-label, parallel-group trial 16-week treatment duration using either or insulin. Insulin was administered twice daily two different regimens, before breakfast at bedtime (IDet morn+bed ) 12-h interval 12h ). bedtime. Mealtime given as rapid-acting aspart. RESULTS —With both groups, clinic fasting plasma lower than vs. NPH, −1.5 mmol/l [95% CI −2.51 −0.48], P 0.004; IDet −2.3 (−3.32 −1.29), 0.006 0.004, respectively). The risk minor hypoglycemia groups (25%, 0.046; 32%, 0.002; respectively) last 12 weeks treatment, this being mainly attributable 53% reduction nocturnal group for each not from group, HbA pooled significantly (mean difference −0.18% [−0.34 −0.02], 0.027). Within-person between-day variation self-measured (both −0.8 kg [−1.44 −0.24], 0.006; −0.6 [−1.23 −0.03], 0.040). CONCLUSIONS —Overall improved data provide basis tailoring administration individual person’s needs.